Journey Medical Corporation (DERM)
USD 6.21
(2.99%)
USD 6.21
(2.99%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 52.52 Million USD | 22.44% |
| 2022 | 42.89 Million USD | 38.14% |
| 2021 | 31.05 Million USD | 3.72% |
| 2020 | 29.93 Million USD | 22.75% |
| 2019 | 24.38 Million USD | -40.75% |
| 2018 | 41.16 Million USD | 806.47% |
| 2017 | 4.54 Million USD | -79.89% |
| 2016 | 22.58 Million USD | 209.38% |
| 2015 | 7.3 Million USD | 0.0% |
| 2014 | 7.3 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 8.31 Million USD | 33.79% |
| 2024 Q1 | 6.21 Million USD | -32.76% |
| 2023 FY | 52.52 Million USD | 22.44% |
| 2023 Q3 | 28.11 Million USD | 198.88% |
| 2023 Q4 | 9.24 Million USD | -67.12% |
| 2023 Q1 | 5.76 Million USD | -30.12% |
| 2023 Q2 | 9.4 Million USD | 63.17% |
| 2022 Q2 | 10.65 Million USD | -29.38% |
| 2022 FY | 42.89 Million USD | 38.14% |
| 2022 Q1 | 15.09 Million USD | 88.85% |
| 2022 Q4 | 8.24 Million USD | -7.27% |
| 2022 Q3 | 8.89 Million USD | -16.54% |
| 2021 Q2 | 7.8 Million USD | 14.58% |
| 2021 Q3 | 8.44 Million USD | 8.19% |
| 2021 Q4 | 7.99 Million USD | -5.34% |
| 2021 FY | 31.05 Million USD | 3.72% |
| 2021 Q1 | 6.81 Million USD | -27.86% |
| 2020 Q3 | 6.06 Million USD | -3.54% |
| 2020 FY | 29.93 Million USD | 22.75% |
| 2020 Q2 | 6.29 Million USD | -12.79% |
| 2020 Q4 | 9.44 Million USD | 55.6% |
| 2020 Q1 | 7.21 Million USD | 0.0% |
| 2019 Q1 | 1.52 Million USD | 17.02% |
| 2019 FY | 24.38 Million USD | -40.75% |
| 2019 Q3 | 9.6 Million USD | -85.3% |
| 2019 Q2 | 65.31 Million USD | 4179.82% |
| 2018 Q2 | 39.08 Million USD | 12970.23% |
| 2018 Q3 | 480 Thousand USD | -98.77% |
| 2018 Q4 | 1.3 Million USD | 171.67% |
| 2018 FY | 41.16 Million USD | 806.47% |
| 2018 Q1 | 299 Thousand USD | -77.74% |
| 2017 Q1 | 1.06 Million USD | -95.26% |
| 2017 FY | 4.54 Million USD | -79.89% |
| 2017 Q4 | 1.34 Million USD | 25.98% |
| 2017 Q3 | 1.06 Million USD | 0.0% |
| 2017 Q2 | 1.06 Million USD | 0.0% |
| 2016 Q4 | 22.46 Million USD | 18778.99% |
| 2016 Q3 | 119 Thousand USD | 0.0% |
| 2016 FY | 22.58 Million USD | 209.38% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | -100.0% |
| 2015 Q1 | - USD | -100.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q3 | 7.3 Million USD | 0.0% |
| 2015 FY | 7.3 Million USD | 0.0% |
| 2015 Q4 | 7.3 Million USD | 0.0% |
| 2014 Q4 | 7.3 Million USD | 0.0% |
| 2014 FY | 7.3 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 83.898% |
| Embecta Corp. | 749.9 Million USD | 92.996% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 82.797% |
| Dynavax Technologies Corporation | 182.11 Million USD | 71.161% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 28.119% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 89.288% |
| PainReform Ltd. | -15 Thousand USD | 350240.0% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -76.529% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -529.811% |
| SCYNEXIS, Inc. | 124.51 Million USD | 57.82% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -9380.821% |
| Cosmos Health Inc. | 4.34 Million USD | -1107.499% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -529.811% |
| Safety Shot Inc | -74.45 Thousand USD | 70638.7% |
| Alpha Teknova, Inc. | 10.29 Million USD | -410.111% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 87.804% |
| Bright Green Corporation | -237.01 Thousand USD | 22259.264% |
| Procaps Group, S.A. | 239.56 Million USD | 78.077% |
| Theratechnologies Inc. | 62.12 Million USD | 15.465% |
| Harrow Health, Inc. | 90.55 Million USD | 42.0% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -1006.87% |
| Biofrontera Inc. | 16.62 Million USD | -215.878% |
| DURECT Corporation | 6.83 Million USD | -668.863% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 89.972% |
| Cronos Group Inc. | 6.99 Million USD | -651.277% |
| OptiNose, Inc. | 62.35 Million USD | 15.77% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 88.095% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 17433.663% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -1619.647% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 83.046% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -873.6% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -56.845% |
| Radius Health, Inc. | 307.71 Million USD | 82.932% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -421.151% |
| ProPhase Labs, Inc. | 16.23 Million USD | -223.425% |
| Phibro Animal Health Corporation | 312.48 Million USD | 83.193% |
| Procaps Group S.A. | 239.56 Million USD | 78.077% |
| Alvotech | -69.42 Million USD | 175.655% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -3933.871% |
| Viatris Inc. | 6.43 Billion USD | 99.184% |
| Rockwell Medical, Inc. | 8.7 Million USD | -503.412% |
| Aytu BioPharma, Inc. | 54.58 Million USD | 3.783% |
| SIGA Technologies, Inc. | 122.09 Million USD | 56.982% |
| Tilray Brands, Inc. | 223.35 Million USD | 76.485% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -25.498% |
| Shineco, Inc. | 882.16 Thousand USD | -5853.628% |
| PetIQ, Inc. | 252.74 Million USD | 79.219% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 7144.239% |
| Incannex Healthcare Limited | 12 Thousand USD | -437575.0% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 97.157% |
| Alimera Sciences, Inc. | 61.17 Million USD | 14.139% |
| Silver Spike Investment Corp. | 8.1 Million USD | -548.199% |
| Assertio Holdings, Inc. | 125.04 Million USD | 58.0% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 771220.247% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -1153.135% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -701.113% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 2279.135% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -93.683% |
| Hempacco Co., Inc. | -1.21 Million USD | 4419.754% |
| Talphera, Inc. | -4.89 Million USD | 1172.952% |
| Alvotech | -69.42 Million USD | 175.655% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 76.307% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 92.598% |
| Currenc Group, Inc. | 17.35 Million USD | -202.605% |
| Kamada Ltd. | 52.59 Million USD | 0.136% |
| Indivior PLC | 907 Million USD | 94.209% |
| Evoke Pharma, Inc. | 4.97 Million USD | -954.903% |
| Flora Growth Corp. | 17.73 Million USD | -196.093% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 2279.135% |
| Evolus, Inc. | 140.52 Million USD | 62.625% |
| HUTCHMED (China) Limited | 453.55 Million USD | 88.42% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 84.731% |
| Akanda Corp. | 111.44 Thousand USD | -47025.591% |